{3-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-isoxazol-5-yl}-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-methanone | 1240402-44-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: {3-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-isoxazol-5-yl}-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-methanone
• 英文别名: [3-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]-1,2-oxazol-5-yl]-(2-oxa-6-azaspiro[3.3]heptan-6-yl)methanone
• CAS: 1240402-44-1
• 化学式: C₂₀H₁₈FN₃O₅
• 分子量: 399.378
• InChiKey: RHXUULYIXRUOQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  90.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-氧杂-6-氮杂-螺[3,3]庚烷草酸盐 、 3-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-isoxazole-5-carboxylic acid methyl ester 在 三甲基铝 作用下， 以 正己烷 、 甲苯 为溶剂， 反应 5.0h， 以8%的产率得到{3-[3-(4-Fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-isoxazol-5-yl}-(2-oxa-6-aza-spiro[3.3]hept-6-yl)-methanone
  参考文献：
  名称：

  ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES

  摘要：

  本发明涉及具有亲和力和选择性作用于GABA A α5受体的式I的异噁唑-异噁唑和异噁唑-异硫唑化合物，其制备方法，含有它们的药物组合物以及它们作为认知增强剂或用于治疗和/或预防认知障碍如阿尔茨海默病的用途。

  公开号：

  US20100210651A1

文献信息

• Isoxazole-isoxazoles and isoxazole-isothiazoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US08173652B2

  公开（公告）日：2012-05-08

  The present invention is concerned with isoxazole-isoxazoles and isoxazole-isothiazoles of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.

  本发明涉及式I的异噁唑-异噁唑和异噁唑-异硫唑，具有亲和力和选择性对于GABA A α5受体，它们的制造，含有它们的制药组合物以及它们作为认知增强剂的用途或治疗和/或预防认知障碍如阿尔茨海默病的药物治疗。
• ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2398782A1

  公开（公告）日：2011-12-28
• METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY
  申请人：Carmichael Stanley T.

  公开号：US20130150351A1

  公开（公告）日：2013-06-13

  Methods for treating a central nervous system (CNS) injury in a subject are provided. As of the methods include administering to the subject an effective amount of gamma aminobutyric acid (GABA) receptor signaling inhibitor to treat the subject for the CNS injury. Also provided are compositions useful in embodiments of the methods. Methods and compositions of the invention find use in the treatment of a variety of different CNS injuries, including but not limited to, treating a subject for CNS injury associated with the occurrence of stroke.
• US8173652B2
  申请人：——

  公开号：US8173652B2

  公开（公告）日：2012-05-08
• [EN] ISOXAZOLE-ISOXAZOLE AND ISOXAZOLE-ISOTHIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOXAZOLE-ISOXAZOLE ET D'ISOXAZOLE-ISOTHIAZOLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010094669A1

  公开（公告）日：2010-08-26

  The present invention is concerned with isoxazole-isoxazole and isoxazole-isothiazole derivatives of Formula (I), having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.